• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267

Research Brief on 1-METHYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE (CAS: 78999-61-8): Recent Advances and Applications

1-METHYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE (CAS: 78999-61-8) is a pyrimidine derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive compounds, particularly in the development of antiviral and anticancer agents. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, biological activities, and potential clinical applications.

Recent investigations into the molecular structure of 1-METHYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE have revealed its unique ability to interact with various biological targets. For instance, studies published in 2023 demonstrated its inhibitory effects on viral polymerases, suggesting its potential as a broad-spectrum antiviral agent. Additionally, its role in modulating cellular pathways involved in apoptosis and inflammation has been explored, further expanding its therapeutic potential. These findings underscore the compound's versatility and its relevance in drug discovery.

In terms of synthetic applications, researchers have developed novel methodologies for the efficient production of 1-METHYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE. A 2024 study published in the Journal of Medicinal Chemistry reported a high-yield, scalable synthesis route that minimizes environmental impact while maintaining high purity. This advancement is particularly significant for industrial-scale production, as it addresses previous challenges related to cost and sustainability. The study also highlighted the compound's stability under various conditions, making it a reliable candidate for further pharmaceutical development.

From a clinical perspective, preclinical trials have shown promising results for 1-METHYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE in animal models of cancer and viral infections. A recent study conducted by a leading research institution demonstrated its efficacy in reducing tumor growth and viral load, with minimal adverse effects. These findings have paved the way for upcoming Phase I clinical trials, which are expected to commence in late 2024. The compound's favorable pharmacokinetic profile and low toxicity further support its potential as a future therapeutic agent.

In conclusion, 1-METHYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE (CAS: 78999-61-8) represents a promising candidate in the field of chemical biology and pharmaceutical research. Its diverse biological activities, coupled with recent advancements in synthesis and preclinical evaluation, highlight its potential for addressing unmet medical needs. Future research should focus on elucidating its mechanisms of action and optimizing its therapeutic efficacy in human trials. This compound exemplifies the intersection of chemistry and biology, offering new avenues for drug discovery and development.

• 21579-19-1(5-Pyrimidinecarboxaldehyde, 1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-)
• 31167-29-0(2,4(1H,3H)-Pyrimidinedione, 1-[3-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)propyl]-5-methyl-)
• 4401-71-2(1,3,5-Trimethylpyrimidine-2,4(1H,3H)-dione)
• 55265-55-9(2,4(1H,3H)-Pyrimidinedione, 1,1'-(1,3-propanediyl)bis[3,5-dimethyl-)
• 35824-98-7(1,3-Dimethyl-5-(dimethylamino)methylene2,4,6-(1H,3H,5H)-trioxopryimidine)
• 874278-95-2(5-Pyrimidinecarboxaldehyde, 1-butyl-1,2,3,4-tetrahydro-2,4-dioxo-)
• 4869-46-9(1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde)
• 22917-75-5(2,4(1H,3H)-Pyrimidinedione,1,1'-(1,3-propanediyl)bis[5-methyl-)
• 38009-11-9(1,3-DIMETHYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE)
• 89227-66-7(2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[(dimethylamino)methylene]-1-methyl-)